Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. Homo sapiens

After 2 and 12 weeks of treatment, we observed significant reductions of 51% and 72%, respectively, in SCORAD scores. Clinical improvements were associated with significant gene expression changes in lesional but also nonlesional skin, particularly reductions in levels of TH2-, TH22-, and some TH17-related molecules (ie, IL-13, IL-22, CCL17, S100As, and elafin/peptidase inhibitor 3), and modulation of epidermal hyperplasia and differentiation measures. Overall design: CsA's effects on AD skin pathology were evaluated by using gene expression and immunohistochemistry studies in baseline, week 2, and week 12 lesional and nonlesional biopsy specimens from 19 patients treated with 5 mg/kg/d CsA for 12 weeks.

在治疗2周与12周后，我们观测到SCORAD评分（Scoring Atopic Dermatitis）分别显著降低51%与72%。临床改善与皮损及非皮损皮肤的显著基因表达变化密切相关，具体表现为辅助性T细胞2（TH2）、辅助性T细胞22（TH22）及部分辅助性T细胞17（TH17）相关分子（即白细胞介素13（IL-13）、白细胞介素22（IL-22）、趋化因子配体17（CCL17）、S100蛋白家族（S100As）及elafin/peptidase inhibitor 3）的水平显著下调，同时伴随表皮增生与分化相关指标的调控变化。整体实验设计：本研究采用基因表达与免疫组化检测手段，对19名每日接受5mg/kg CsA（环孢素A，cyclosporine A）治疗12周的AD（特应性皮炎，Atopic Dermatitis）患者，分别在基线、治疗第2周及第12周时采集的皮损与非皮损皮肤活检样本进行分析，以此评估CsA对AD皮肤病理的干预效果。